Sigma Bio's organoid-plus-AI drug discovery platform and SIGX1094 candidate
Overview
Sigma Bio CTO Zhuo Zhuo says the company's SIGX1094 candidate for diffuse gastric cancer is in clinical trials and has received US orphan drug and fast-track designations.
Zhuo says the company built an organoid-plus-AI platform with XtalPi that feeds experimental efficacy and safety data back into AI molecule design.
Zhuo also says China's drug regulator is validating organoids as an alternative to animal testing, and that Sigma Bio is the only company among seven participating institutions. The report does not include the regulator's own statement on the validation.
Written by AI from the articles below · updated Oct 30, 8:46 AM ET
Check the sources:
Article timeline
The articles in this story. Times are ET.
- LeiphoneNewsSigma Bio's CTO describes organoid-plus-AI drug discovery a year after Galien nomination
AISigma Bio CTO Zhuo Zhuo says the company's SIGX1094 candidate for diffuse gastric cancer is in clinical trials, and it has received orphan drug and fast-track designations in the US. Zhuo says the company's organoid-plus-AI platform, built with XtalPi, feeds experimental efficacy and safety data back into AI molecule design. He also says China's drug regulator is validating organoids as an alternative to animal testing, and Sigma Bio is the only company among seven participating institutions.
Heat Trend
- Current comparable heat
- 9
- Peak comparable heat
- 9Oct 30, 9:00 AM ET
- Change in past 24 hours
- –
The trend compares only continuously observed participants, so its scope may be smaller than the current heat total. Hover or tap for hourly heat; use arrow keys with a keyboard.